Related Research Articles
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
Sigma Healthcare Limited is an Australian, ASX-listed company with a focus on the pharmacy industry. The company has pharmacy operations in retail, wholesale and distribution. From its head office in Clayton, Victoria, Sigma manages over 1,200 branded and independent pharmacies. Sigma Healthcare owns Australian retail pharmacy brands: Amcal, Discount Drug Stores and Guardian Pharmacy. The company also has a presence in the hospital pharmacy services, contract logistics, dose administration aids and other healthcare service adjacencies.
Sons of Gwalia was a Western Australian mining company that mined gold, tantalum, spodumene, lithium and tin. It was Australia's third-largest gold producer and controlled more than half the world's production of tantalum, before entering administration in August 2004 following a financial collapse.
John Andrew Henry Forrest, nicknamed Twiggy, is an Australian businessman. He is best known as the former CEO of Fortescue Metals Group (FMG), and has other interests in the mining industry and in cattle stations.
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services.
Patrick Soon-Shiong is a South African and American businessman, investor, medical researcher, philanthropist, and transplant surgeon. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.
The King of the Hills Gold Mine, formerly the Tarmoola Gold Mine, is located 29 km north-west of Leonora, Western Australia. The mine was placed in care and maintenance from September 2004, when a pit wall failure forced its closure. It is owned by Saracen Mineral Holdings Limited.
Normandy Mining was an Australian mining company which predominantly mined gold. Normandy was, during much of the late 20th century, Australia's largest gold miner.
The Randalls Gold Mine is a gold mine, recently developed, located 36 km east-north-east of Kambalda, Western Australia, near Mount Monger Station.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Martin Rogers is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Tattarang is an Australian private investment company owned by Andrew Forrest and his family. Tattarang invests in a diverse range of businesses across agri-food, energy, health technology, property, resources, and lifestyle. The group is made up of six business divisions: Fiveight, Harvest Road, Squadron Energy, Tenmile, Wyloo Metals and Z1Z.
References
- ↑ Thomson, James (18 July 2010). "Medical company backed by mining billionaire Andrew Forrest launches biotech investment push". SmartCompany. Retrieved 14 March 2023.
- ↑ Greenblat, Eli (18 July 2010). "Mining magnate invests in biotech". The Sydney Morning Herald. Retrieved 15 March 2023.
- 1 2 Evans, Nick (15 February 2011). "Forrest biotech company to list". PerthNow. Retrieved 15 March 2023.
- ↑ Evans, Nick (31 May 2011). "BioMD's Allied takeover wrapping up soon". PerthNow. Retrieved 15 March 2023.
- ↑ Stafford, Patrick (20 June 2011). "Andrew Forrest-backed biotech lists on ASX". SmartCompany. Archived from the original on 24 June 2011. Retrieved 15 March 2023.
- ↑ "bioMD Limited Makes Offer for Unlisted Allied Medical to Create Diversified Healthcare Group" (Press release). BioSpace. 15 February 2011. Retrieved 16 March 2023.
- 1 2 Drummond, Cameron (12 December 2013). "Biotech company buys manufacturing facility". Business News. Retrieved 15 March 2023.
- ↑ Smith, Sean (21 November 2013). "Allied rebrands as Admedus". The West Australian. Retrieved 15 March 2023.
- 1 2 "Admedus sells its CardioCel and VascuCel patch business for $A36.2m". Australian Manufacturing. 16 October 2019. Retrieved 15 March 2023.
- ↑ Ford, Omar (14 October 2019). "Admedus Turns Attention to TAVR Program". mddionline.com. Retrieved 15 March 2023.
- ↑ Anderson, Caitlin (21 February 2023). "Med-device company Anteris Technologies raises $24 million". www.bizjournals.com. Retrieved 8 August 2024.